Kyverna Therapeutics
9 articles with Kyverna Therapeutics
-
Kyverna Therapeutics Closes $85 Million Series B Financing led by Northpond Ventures
1/26/2022
Kyverna Therapeutics, a cell therapy company engineering a new class of therapies for serious autoimmune diseases, announced it has closed an oversubscribed $85 million Series B financing round led by Northpond Ventures.
-
The amount will be used to enhance research and development efforts for KYV-101 that has a strong potential to treat different types of autoimmune illnesses.
-
Intellia Therapeutics and Kyverna Therapeutics Announce Collaboration to Develop Next-Generation Allogeneic T-Cell Therapy for Autoimmune Diseases
1/5/2022
Intellia grants Kyverna exclusive rights to its differentiated allogeneic cell engineering platform for the development of KYV-201, a next-generation CD19 CAR T-cell therapy to treat autoimmune diseases.
-
Intellia and Kyverna announced an exclusive agreement to develop and later commercialize an allogeneic CD19 CAR T-cell therapy to treat a wide range of B cell-mediated autoimmune illnesses.
-
Kyverna Therapeutics Announces Exclusive Worldwide Licenses With National Institutes of Health for Autologous and Allogeneic Anti-CD19 CAR T Cellular Therapies to Treat Autoimmune Diseases
1/3/2022
Kyverna Therapeutics today announced that the company has entered into exclusive, worldwide licenses with the National Institutes of Health (NIH) for intellectual property related to a novel clinical-stage anti-CD19 chimeric antigen receptor T-cell (CAR T) construct with properties uniquely suited for use in autoimmune diseases.
-
This California biotech just bagged another partner for its endeavor to cure autoimmune disease with cell therapy.
-
Kyverna Therapeutics Appoints Ian Clark as Chairman of the Board and Karen Walker as Chief Technology Officer
9/15/2021
Kyverna Therapeutics, Inc., today announced the appointment of Ian Clark as chair of the company's board of directors and the appointment of Karen Walker as Chief Technology Officer (CTO).
-
Kyverna Therapeutics Announces the Appointment of James Chung, M.D., Ph.D., as Chief Medical Officer
4/13/2021
Dr. Chung brings nearly 20 years' experience as a leader in autoimmune disease drug development with expertise in rheumatology, autoimmunity, and immunology Company also names world's leading immunology experts to Scientific Advisory Board
-
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life sciences companies in North America that recently launched.